

Appendix C – Key dates for the Post-market Review of Ezetimibe

Date	Milestone	Notes
14 August 2015	PBAC recommended Post-market Review	Purpose of the Review was to consider cost-effectiveness
28 September 2015	Ministerial approval to commence Review	NA
16 October – 13 November 2015	Public consultation on draft TOR (4 weeks)	Consultation period was initially due to end 30 October 2015 but was extended. Five submissions were received.
11 December 2015	PBAC considered final TOR	NA
24 February 2016	Ministerial approval of final TOR	NA
4 March 2016 – 22 April 2016	Public consultation on final TOR (7 weeks)	Six submissions received.
10 May 2016	Engaged evaluator group	Official order between the Department of Health and Deakin University signed
30 June 2016	Reference Group meeting 1	Ten Reference Group members attended. <u>Discussed:</u> <ul style="list-style-type: none"> • TOR • Consumer and stakeholder input • Evidence evaluation – Research questions for Literature Review; Utilisation Review
23 September 2016	Draft report from evaluator group	NA
23 September 2016	Reference Group meeting 2	Twelve Reference Group members attended. <u>Discussed:</u> <ul style="list-style-type: none"> • Review progress • Evidence evaluation - Final research protocol; draft Literature Review report; draft Utilisation Review report • External reports • Stakeholder forum
11 November 2016	Stakeholder forum	Outcome statement at Appendix F
23 November 2016	Final report from evaluator group	NA
30 November 2016	Reference Group meeting 3	12 Reference Group members attended. <u>Discussed</u> <ul style="list-style-type: none"> • Draft Review Report
22 December 2016	Draft Review Report to ezetimibe sponsor	NA
25 January 2017	Pre subcommittee response received from sponsor (draft Review Report)	NA
30 January- 10 February 2017	Public consultation on draft Review Report (2 weeks)	14 submissions received
2-7 February 2017	ESC/DUSC consideration of draft Review Report	Further analysis requested

Date	Milestone	Notes
14 March 2017	ESC/DUSC advice provided to sponsor	NA
17 March 2017	Reference Group Meeting 4 (to finalise the draft Review Report)	Ten Reference Group members attended. <u>Discussed:</u> <ul style="list-style-type: none"> Stakeholder submissions Finalise Review Report
29 March 2017	Sponsor pre PBAC response received (draft Review Report) ¹	NA
10 May 2017	<i>Revised</i> draft Review Report to sponsor	NA
23 May-6 June 2017	Public consultation on <i>revised</i> draft Review Report	7 submissions received
24 May 2017	Pre subcommittee response received from sponsor (<i>revised</i> draft Review Report)	NA
1-6 June 2017	ESC/DUSC consideration of <i>revised</i> draft Review Report	NA
21 June 2017	ESC/DUSC advice provided to sponsor	NA
28 June 2017	Sponsor pre PBAC response due	NA
5-7 July 2017	PBAC consideration of Review Report and advice to Government	NA
Mid-late 2017	Ministerial consideration of Review Report	NA

Abbreviations: ESC, Economics Sub Committee; DUSC, Drug Utilisation Sub Committee; NA, Not applicable; TOR, Terms of Reference.

¹ The *original* draft Review Report was not considered by the PBAC in March 2017.